- Home
- » Tags
- » Rosiglitazone
Top View
- Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer
- Product Monograph
- Clinical Review Hyon Kwon, Pharmd, MPH Snda 208751/S-010 and S-011 Fiasp (Insulin Aspart)
- Dual Pparα/Γ Activation Inhibits SIRT1-Pgc1α Axis and Causes Cardiac Dysfunction
- Insulin Overview
- Over 10 Years After the Diabetes Drug Rosiglitazone Was Approved by Regulators, and Despite Studies on Tens of Thousands Of
- An Endogenous Peroxisome Proliferator-Activated Receptor ␥ Ligand
- Specific Inhibition of the Distribution of Lobeglitazone to the Liver
- EGFR Signaling and the Anti- Cancer Effects of Thiazolinedinediones Jesse Roman1
- A Novel Pparγ Agonist, SP1818, Shows Different Coactivator Profile with Rosiglitazone
- The Effect of Antidiabetic Medications on Non-Alcoholic Fatty Liver Disease
- Comparison of Insulin Degludec/Insulin
- Rosiglitazone Suppresses Human Lung Carcinoma Cell Growth Through PPAR;-Dependent and PPAR;-Independent Signal Pathways
- Elucidation of Molecular Mechanism of a Selective PPAR Modulator
- Avandia Label
- Insulin Overview
- Insulin Degludec/Insulin Aspart (Degludecplus) for Type 2 Diabetes
- Insulin Lispro | Memorial Sloan Kettering Cancer Center
- Diabetes Medications Timeline of Insulin Therapies in the US
- Anti-Diabetic Agents
- PPAR-Mediated Toxicology and Applied Pharmacology
- The Antidiabetic Drug Lobeglitazone Protects Mice from Lipogenesis-Induced Liver Injury Via Mechanistic Target of Rapamycin Complex 1 Inhibition
- Original Article
- Pioglitazone and Rosiglitazone
- Improvement of Glycemic Control, Triglycerides, And
- Supplementary Materials: Building and Testing Pparγ Therapeutic ELB00824 with an Improved Therapeutic Window for Neuropathic Pain
- Avandia, INN-Rosiglitazone
- Pparγ-Independent Side Effects of Thiazolidinediones on Mitochondrial Redox State in Rat Isolated Hearts
- Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
- Comparison of PPAR Ligands As Modulators of Resolution of Inflammation, Via Their Influence on Cytokines and Oxylipins Release in Astrocytes
- Risk Assessment and Risk Mitigation Review(S)
- Adding Insulin Glargine Vs. Rosiglitazone: Health-Related Quality of Life Impact in Type 2 Diabetes
- And Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Non-Pregnant Adults with Diabetes Mellitus
- Mechanistic Insights Into Side Effects of Troglitazone and Rosiglitazone Using a Novel Inverse Molecular Docking Protocol
- New Drug Evaluation: Insulin Degludec/Aspart, Subcutaneous Injection
- Current Drug Targets, 2018, 19, 663-673 REVIEW ARTICLE
- Adding Insulin Glargine Versus Rosiglitazone Health-Related Quality-Of-Life Impact in Type 2 Diabetes
- Identification of a Novel PPAR
- Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients with Type 2 Diabetes Mellitus the Alecardio Randomized Clinical Trial
- Rosiglitazone (Avandia®▼)
- Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
- Updating Insights Into Rosiglitazone and Cardiovascular Risk BMJ: First Published As 10.1136/Bmj.L7078 on 5 February 2020
- Insulin Degludec Insulin Aspart (Ryzodeg 70 30) Prescribing Protocol.Pdf
- PPAR) Gamma Agonists and Antagonists
- Use of Antidiabetic Drugs in the U.S., 2003–2012
- Lessons from the Avandia Controversy a New Paradigm for the Development of Drugs to Treat Type 2 Diabetes
- Effects of Metformin and Rosiglitazone Treatment on Insulin Signaling and Glucose Uptake in Patients with Newly Diagnosed Type 2
- Saroglitazar, a Novel Cardiometabolic Agent for Diabetic Dyslipidemia – a Review
- Saroglitazar: India's Answer to Diabetic Dyslipidemia
- Pharmacogenetic Analysis of Rosiglitazone-Induced Hepatosteatosis in New Mouse Models of Type 2 Diabetes Huei-Ju Pan,1 Peter Reifsnyder,1 Dennis E
- 209196Orig1s000